Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Study Details
Study Description
Brief Summary
This study will evaluate the effectiveness of Treximet when taken for post traumatic headache by measuring any change in the number of headache days or any change in a subject's ability to think following treatment with study medication. Eligible subjects will complete 3 visits. Following Visit 1, subjects will treat with their usual medication and document headache symptoms and therapy in a Headache Diary. After 30 days, subjects will return for Visit 2 and be randomized (like the flip of a coin) to receive Treximet or matching placebo to treat at the same time each day. Treximet will be provided to treat any headache that occurs. Subjects will complete a daily Diary. After 30 days, subjects will exit the study at Visit 3.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Subjects will be enrolled at 3 investigative sites. At Visit 1, a medical, headache, and medication history will be collected and a physical and neurological exam with vital signs will be performed. An ECG will be completed if one has not been completed in the previous 6 months. Subjects will be administered a series of psychological tests to help the study doctor decide whether or not a subject is eligible. The Headache Impact Test-6 and Migraine Specific Quality of Life Questionnaire will be completed at each visit. During a 30-day Baseline Period, subjects will treat with their usual medication and complete a daily Diary documenting headache symptoms and treatment. At Visits 2 and 3 subjects will complete the Mental Efficiency Workload Test and Migraine Early Warning Tool. Following randomization at Visit 2, subjects will treat daily for 30 days with Treximet or a matching placebo. Subjects will be provided with Treximet for rescue of any persisting or recurring headache. During the Treatment Period, subjects will complete a daily Diary reporting headache symptoms and response to treatment. After the 30-day Treatment Period, subjects will exit the study at Visit 3 .
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Treximet In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days. |
Drug: sumatriptan/naproxen sodium
Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
Other Names:
|
| Placebo Comparator: Placebo In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet. |
Drug: Placebo
Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
|
Outcome Measures
Primary Outcome Measures
- Headache Days [Day 0, Day 30]
Change in number of headache days at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm.
- Change in Number of Associated Headache Symptoms [Day 0, Day 30]
Change in number of associated headache symptoms at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm. Associated headache symptoms measured included number of incidences of: sleeplessness, difficulty thinking, and bodily pain.
Secondary Outcome Measures
- Mental Efficiency Workload Test (MEWT) Performance Index [Day 0, Day 30]
The Mental Efficiency Workload Test (MEWT) performance index is a scale with minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning.
- Headache Impact Test-6 (HIT-6) Score [Day 0, Day 30]
The Headache Impact Test-6 (HIT-6) scale measures the impact of headache symptoms on subject's life. Possible scores range from 36 to 78. Score of 48 or less indicates headache has little impact on life. Score of 60-78 indicative of very severe impact.
- Migraine Specific Quality of Life Questionnaire (MSQ) [Day 0, Day 30]
The Migraine-Specific Quality of Life Questionnaire (MSQ) is a scale that measures the impact of migraine across three aspects: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Possible scores on each subscale range from a 0 to 100 scale such that higher scores indicate better quality of life.
Eligibility Criteria
Criteria
Inclusion Criteria:
Subject
-
is male or female between the ages of 18-65. A female is eligible to enter and participate in this study if she is of: a.non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,b. child-bearing potential, has a negative pregnancy test (urine or serum) at Visit 2, and agrees to one of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the investigational product, throughout the study, and for a time interval (5 days) after completion or premature discontinuation from the study to account for elimination of the investigational drug; subjects utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent when they present to the clinic for the final visit or, Female sterilization; or, Sterilization of male partner; or, Implants of levonorgestrel; or, Injectable progestogen; or, Oral contraceptive (combined or progestogen only); or, Any intrauterine device (IUD) with published data showing that the highest expected failure rate is less than 1% per year (not all IUDs meet this criterion); or, Spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a female diaphragm); or, Any other barrier methods (only if used in combination with any of the above acceptable methods); or, Any other methods with published data showing that the highest expected failure rate for that method is less than 1% per year.
-
is formally diagnosed with International Classification of Headache Disorders (ICHD) 5.2.2 chronic post traumatic headache
-
has >15 headache days per month in past 3 months
-
has headache that, if left untreated, would have at least 1 symptom of migraine (nausea, vomiting, photophobia, or phonophobia) or respond to a triptan or ergotamine-containing medication with at least 50% of headaches
-
is medically stable as determined by the Investigator
-
if taking a headache preventive medication, has been on a stabilized dosage for at least 30 days prior to screening.
-
if taking any concomitant medications, is on a stabilized dosage at the discretion of the investigator
-
has chronic headache history only after the traumatic brain injury (TBI)
-
is able to understand and communicate intelligibly with the study observer
-
is able to take oral medication, adhere to the medication regimens and perform study procedures
-
is able to read and comprehend written instructions and be willing to complete all procedures and assessments required by this protocol
-
is able to demonstrate the willingness to participate by signing and understanding an informed consent after full explanation of the study
-
has self-reported cognitive inefficiency or "brain-fog" during headache
Exclusion Criteria:
Subject
-
has a history of serotonin syndrome
-
has any medical condition that, in the opinion of the investigator, could alter the response to study medication or confound the results of the study
-
is female of childbearing potential not using adequate contraceptive measures
-
has history of retinal, basilar or hemiplegic migraine, cluster headache, or secondary headaches (such as due to infection, alterations of homeostasis, ear nose and throat (ENT) or psychiatric disorders, cranial or cervical disorders or neuralgias)
-
in the investigator's opinion, is likely to have unrecognized cardiovascular or cerebrovascular disease (based on history or the presence of risk factors including but not limited to, hypertension, hypercholesterolemia, smoker, obesity, diabetes, or family history of coronary artery disease)
-
has blood pressure ≥140/90 millimeters of mercury (mmHg) in 2 out of 3 BP measurements at screening or is taking any angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker
-
has a history of significant congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study
-
has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's Syndrome, or signs/symptoms consistent with any of the above
-
has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold; or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening
-
has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study
-
has hypersensitivity, intolerance, or contraindication to the use of any triptan, nonsteroidal antiinflammatory drug (NSAID) or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma
-
is currently taking, or has taken in the previous three months, a migraine prophylactic medication containing methysergide; or is taking a migraine or menstrual migraine prophylactic medication that is not stabilized (i.e. start or change of dose within 30 days prior to screening)
-
has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain or any medication overuse that in the opinion of the investigator has exacerbated or contributed to the current headache pattern of the subject.
-
has taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal preparations containing St. John's Wort (Hypericum perforatum), anytime within the 2 weeks prior to screening through 2 weeks post final study treatment.
-
has history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.
-
has evidence or history of any gastrointestinal surgery or GI ulceration or perforation in the past six months, gastrointestinal bleeding in the past year; or evidence or history of inflammatory bowel disease
-
is pregnant, actively trying to become pregnant, or breast feeding
-
has evidence of alcohol or substance abuse within the last year or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial.
-
has participated in an investigational drug trial within the previous four weeks or plans to participate in another study at any time during this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Clinvest | Springfield | Missouri | United States | 65807 |
| 2 | Nashville Neuroscience Group, PC | Nashville | Tennessee | United States | 37203 |
| 3 | Scott & White Memorial Hospital and Clinic | Temple | Texas | United States | 76508 |
Sponsors and Collaborators
- Cady, Roger, M.D.
- GlaxoSmithKline
Investigators
- Principal Investigator: Roger K Cady, MD, Clinvest
Study Documents (Full-Text)
None provided.More Information
Publications
- Baandrup L, Jensen R. Chronic post-traumatic headache--a clinical analysis in relation to the International Headache Classification 2nd Edition. Cephalalgia. 2005 Feb;25(2):132-8. Erratum in: Cephalalgia. 2005 Mar;25(3):240.
- Cady R, Farmer K. Soft tissue injuries: diagnosis and treatment. Posttraumatic headache. In Windsor R, Lox D (eds.) Hanley and Belfus, Inc. Philadelphia, PA. 207-224.
- Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160.
- 114126
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Treximet | Placebo |
|---|---|---|
| Arm/Group Description | In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days. sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet. Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. |
| Period Title: Overall Study | ||
| STARTED | 11 | 12 |
| COMPLETED | 8 | 11 |
| NOT COMPLETED | 3 | 1 |
Baseline Characteristics
| Arm/Group Title | Treximet | Placebo | Total |
|---|---|---|---|
| Arm/Group Description | In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days. sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet. Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | Total of all reporting groups |
| Overall Participants | 11 | 12 | 23 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
41.36
(9.83)
|
35.83
(12.01)
|
38.48
(11.14)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
6
54.5%
|
9
75%
|
15
65.2%
|
| Male |
5
45.5%
|
3
25%
|
8
34.8%
|
| Region of Enrollment (participants) [Number] | |||
| United States |
11
100%
|
12
100%
|
23
100%
|
Outcome Measures
| Title | Headache Days |
|---|---|
| Description | Change in number of headache days at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm. |
| Time Frame | Day 0, Day 30 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30). |
| Arm/Group Title | Treximet | Placebo |
|---|---|---|
| Arm/Group Description | In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days. sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet. Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. |
| Measure Participants | 7 | 10 |
| Mean (Standard Deviation) [days] |
-3.00
(7.6)
|
-0.30
(5.3)
|
| Title | Change in Number of Associated Headache Symptoms |
|---|---|
| Description | Change in number of associated headache symptoms at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm. Associated headache symptoms measured included number of incidences of: sleeplessness, difficulty thinking, and bodily pain. |
| Time Frame | Day 0, Day 30 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30). |
| Arm/Group Title | Treximet | Placebo |
|---|---|---|
| Arm/Group Description | In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days. sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet. Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. |
| Measure Participants | 7 | 10 |
| Change in Sleeplessness |
2.43
(7.76)
|
-2.30
(3.47)
|
| Change in Difficulty Thinking |
0.14
(12.32)
|
0.00
(4.83)
|
| Change in Bodily Pain |
-1.71
(6.52)
|
-3.80
(5.67)
|
| Title | Mental Efficiency Workload Test (MEWT) Performance Index |
|---|---|
| Description | The Mental Efficiency Workload Test (MEWT) performance index is a scale with minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. |
| Time Frame | Day 0, Day 30 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30). |
| Arm/Group Title | Treximet | Placebo |
|---|---|---|
| Arm/Group Description | In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days. sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet. Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. |
| Measure Participants | 6 | 9 |
| Day 0 |
3.10
(2.28)
|
3.4
(2.27)
|
| Day 30 |
3.17
(2.23)
|
3.11
(2.09)
|
| Title | Headache Impact Test-6 (HIT-6) Score |
|---|---|
| Description | The Headache Impact Test-6 (HIT-6) scale measures the impact of headache symptoms on subject's life. Possible scores range from 36 to 78. Score of 48 or less indicates headache has little impact on life. Score of 60-78 indicative of very severe impact. |
| Time Frame | Day 0, Day 30 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30). |
| Arm/Group Title | Treximet | Placebo |
|---|---|---|
| Arm/Group Description | In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days. sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet. Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. |
| Measure Participants | 7 | 11 |
| Day 0 |
59.43
(6.65)
|
61.91
(3.21)
|
| Day 30 |
58.57
(6.13)
|
61.91
(6.44)
|
| Title | Migraine Specific Quality of Life Questionnaire (MSQ) |
|---|---|
| Description | The Migraine-Specific Quality of Life Questionnaire (MSQ) is a scale that measures the impact of migraine across three aspects: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Possible scores on each subscale range from a 0 to 100 scale such that higher scores indicate better quality of life. |
| Time Frame | Day 0, Day 30 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30). |
| Arm/Group Title | Treximet | Placebo |
|---|---|---|
| Arm/Group Description | In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days. sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet. Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. |
| Measure Participants | 7 | 11 |
| Day 0 - Role Function-Restrictive Score |
60
(12.34)
|
45.71
(16.95)
|
| Day 30 - Role Function-Restrictive Score |
59.59
(23.81)
|
50.39
(19.35)
|
| Day 0 - Role Function-Preventive Score |
79.29
(14.84)
|
68.64
(22.81)
|
| Day 30 - Role Function-Preventive Score |
80
(13.84)
|
69.55
(24.95)
|
| Day 0 - Emotional Function Score |
60
(18.05)
|
50.91
(25.69)
|
| Day 30 - Emotional Function Score |
65.03
(28.76)
|
57.58
(29.25)
|
Adverse Events
| Time Frame | Day 0, Day +30 | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Treximet | Placebo | ||
| Arm/Group Description | In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days. sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet. Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period. | ||
All Cause Mortality |
||||
| Treximet | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Treximet | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/11 (0%) | 0/12 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Treximet | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 7/11 (63.6%) | 11/12 (91.7%) | ||
| Cardiac disorders | ||||
| Increased Heart Rate | 0/11 (0%) | 0 | 1/12 (8.3%) | 7 |
| Ear and labyrinth disorders | ||||
| Ear Ache | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Gastrointestinal disorders | ||||
| Throat Tightness | 0/11 (0%) | 0 | 1/12 (8.3%) | 8 |
| Nausea | 2/11 (18.2%) | 10 | 2/12 (16.7%) | 4 |
| Vomiting | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| General disorders | ||||
| Head Burning Sensation | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Shaking | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Dry Mouth | 1/11 (9.1%) | 5 | 0/12 (0%) | 0 |
| Increased Energy | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Thirsty | 2/11 (18.2%) | 2 | 0/12 (0%) | 0 |
| Excessive Sweating | 2/11 (18.2%) | 4 | 0/12 (0%) | 0 |
| Infections and infestations | ||||
| Sinus Infection | 1/11 (9.1%) | 1 | 1/12 (8.3%) | 1 |
| Fever | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Investigations | ||||
| Elevated Creatinine | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Elevated ALT | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Elevated AST | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Musculoskeletal and connective tissue disorders | ||||
| Chest Pressure | 0/11 (0%) | 0 | 1/12 (8.3%) | 2 |
| Slow Motor Function | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Jaw Ache | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Tooth Ache | 1/11 (9.1%) | 1 | 1/12 (8.3%) | 1 |
| Left Arm Pain | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Left Scapula Pain | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Left Leg Fell Asleep | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Right Arm Tingling | 0/11 (0%) | 0 | 1/12 (8.3%) | 1 |
| Aching Leg Muscles | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Sensations of Needles in Head | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Cramping Sides | 1/11 (9.1%) | 2 | 0/12 (0%) | 0 |
| Calf Cramps | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Nervous system disorders | ||||
| Dizziness | 2/11 (18.2%) | 3 | 1/12 (8.3%) | 1 |
| Drowsy | 2/11 (18.2%) | 2 | 2/12 (16.7%) | 3 |
| Temporal Bilateral Vein Throbbing | 1/11 (9.1%) | 6 | 0/12 (0%) | 0 |
| Light Sensitivity | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Psychiatric disorders | ||||
| Depression | 1/11 (9.1%) | 1 | 1/12 (8.3%) | 1 |
| Moody | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Insomnia | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Renal and urinary disorders | ||||
| Increased Urination | 1/11 (9.1%) | 1 | 0/12 (0%) | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Head Cold | 1/11 (9.1%) | 2 | 3/12 (25%) | 3 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Roger K. Cady |
|---|---|
| Organization | Clinvest/A Division of Banyan Group, Inc. |
| Phone | 417-841-3673 |
| jtarrasch@clinvest.com |
- 114126